We have been busy preparing for a number of upcoming conferences in November1.

At the 2nd International Akademie Fresenius Gene-Tox Conference (November 3, 2022), Kevin Cross will discuss “N-Nitrosamine Impurities in Drugs – Introducing the EMA-Mutamind Project”.

As part of the Extractables & Leachables Europe 2022 Conference (November 7 – 8, 2022) Glenn Myatt will make a presentation on ‘Emerging applications of computational methods in the assessment of extractables and leachables”.

In addition, at the American College of Toxicology’s 43rd Annual Meeting (November 13 – 16, 2022), we will be presenting on “Strategic In Silico: Creating Powerful New Scientific Insights” (Tuesday, November 15, 12.00-12.55pm) as well as participating in Symposium 1 “ICH S1B(Rq): New Approaches in the Carcinogenicity Assessment of Pharmaceuticals” (Monday 14th November 9-12pm MST) and Workshop 4 “Addressing the Global Challenge of Nitrosamine Impurities in Pharmaceutical  Products” (Monday 14th November, 2-5pm MST).

Please let me know if you are interested in discussing any of these presentations (Glenn Myatt; glenn.myatt@instem.com).


  1. https://www.instem.com/news/

Published by Glenn Myatt

Glenn J. Myatt is the co-founder of Leadscope and currently Senior Vice President, In Silico & Translational Science Solutions at Instem with over 30 years’ experience in computational chemistry/toxicology. He holds a Bachelor of Science degree in Computing, a Master of Science degree in Artificial Intelligence and a Ph.D. in Chemoinformatics. He has published 37 papers, 11 book chapters and three books.